Systematic review: does endocrine therapy prolong survival in patients with prostate cancer?

References

• Huggins C, Hodges CV. Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941. J Urol 2002;168:9–12.
   PubMed Web of Science ®Google Scholar
• Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, Mason MD, et al. Guidelines on prostate cancer. European Association of Urology; 2013. Available from http://uroweb.org/wp-content/uploads/09_Prostate_Cancer_LR.pdf
   Google Scholar
• Mottet N, Bastian PJ, Bellmunt J, van den Bergh RCN, Bolla M, van Casteren NJ, et al. Guidelines on prostate cancer. European Association of Urology; 2014. Available from http://uroweb.org/wp-content/uploads/1607-Prostate-Cancer_LRV3.pdf
   Google Scholar
• Thompson IM, Trasher JB, Aus G, Burnett AL, Canby-Hagino ED, Cookson MS, et al. Prostate cancer guideline for the management of clinically localized prostate cancer. 2007 update. J Urol 2007;177:2106–31.
   PubMed Web of Science ®Google Scholar
• Cookson MS, Roth BJ, Dahm P, Engstrom C, Freedland SJ, Hussain M, et al. Castration-resistant prostate cancer: AUA guideline. J Urol 2013;190:429–38.
   PubMed Web of Science ®Google Scholar
• CEBM. Oxford Centre for Evidence-based Medicine – Levels of Evidence (March 2009) Available from http://www.cebm.net/oxford-centre-evidence-based-medicine-levels-evidence-march-2009/
   Google Scholar
• Lekås E, Johansson M, Widmark A, Bergh A, Damber JE. Decrement of blood flow precedes the involution of the ventral prostate in the rat after castration. Urol Res 1997;25:309–14.
   PubMedGoogle Scholar
• Lekås E, Engstrand C, Bergh A, Damber JE. Transient ischemia induces apoptosis in the ventral prostate of the rat. Urol Res 1999;27:174–9.
   PubMedGoogle Scholar
• Shabsigh A, Chang DT, Heitjan DF, Kiss A, Olsson CA, Puchner PJ, et al. Rapid reduction in blood flow to the rat ventral prostate gland after castration: preliminary evidence that androgens influence prostate size by regulating blood flow to the prostate gland and prostatic endothelial cell survival. Prostate 1998;36:201–6.
   PubMed Web of Science ®Google Scholar
• Soloway MS, Sharifi R, Wajsman Z, McLeod D, Wood DP, Puras-Baez A. Randomized prospective study comparing radical prostatectomy alone versus radical prostatectomy preceded by androgen blockade in clinical stage B2 (T2bNxM0) prostate cancer. The Lupron Depot Neoadjuvant Prostate Cancer Study Group. J Urol 1995;154:424–8.
   PubMed Web of Science ®Google Scholar
• Meyer F, Moore L, Bairati I, Lacombe L, Têtu B, Fradet Y. Neoadjuvant hormonal therapy before radical prostatectomy and risk of prostate specific antigen failure. J Urol 1999;162:2024–8.
   PubMed Web of Science ®Google Scholar
• Aus G, Abrahamsson P-A, Ahlgren G, Hugosson J, Lundberg S, Schain M, et al. Three-month neoadjuvant hormonal therapy before radical prostatectomy: a 7-year follow-up of a randomized controlled trial. BJU Int 2002;90:561–6.
   PubMed Web of Science ®Google Scholar
• Soloway MS, Pareek K, Sharifi R, Wajsman Z, McLeod D, Wood DP, et al. Neoadjuvant androgen ablation before radical prostatectomy in cT2bNxMo prostate cancer: 5-year results. J Urol 2002;167:112–16.
   PubMed Web of Science ®Google Scholar
• Roach M, Bae K, Speight J, Wolkov HB, Rubin P, Lee RJ, et al. Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610. J Clin Oncol 2008;26:585–91.
   PubMed Web of Science ®Google Scholar
• Jones CU, Hunt D, McGowan DG, Amin MB, Chetner MP, Bruner DW, et al. Radiotherapy and short-term androgen deprivation for localized prostate cancer. N Engl J Med 2011;365:107–18.
   PubMed Web of Science ®Google Scholar
• Widmark A, Klepp O, Solberg A, Damber J-E, Angelsen A, Fransson P, et al. Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial. Lancet 2009;373:301–8.
   PubMed Web of Science ®Google Scholar
• Fossa SD, Widmark A, Klepp OH, Wiklund F, Angelsen A, Damber J-E. Ten- and 15-year prostate cancer-specific survival in patients with nonmetastatic high-risk prostate cancer randomized to lifelong hormone treatment alone or combined with radiotherapy (SPCG VII). J Clin Oncol 2014;32(Suppl 4): abstract 4.
   Google Scholar
• Mason MD, Parulekar WR, Sydes MR, Brundage M, Kirkbride P, Gospodarowicz M, et al. Final Report of the Intergroup Randomized Study of Combined Androgen-Deprivation Therapy Plus Radiotherapy Versus Androgen-Deprivation Therapy Alone in Locally Advanced Prostate Cancer. J Clin Oncol 2015;33:2143–50.
   PubMed Web of Science ®Google Scholar
• Iversen P, McLeod DG, See WA, Morris T, Armstrong J, Wirth MP. Antiandrogen monotherapy in patients with localized or locally advanced prostate cancer: final results from the bicalutamide Early Prostate Cancer programme at a median follow-up of 9.7 years. BJU Int 2010;105:1074–81.
   PubMed Web of Science ®Google Scholar
• Pilepich MV, Winter K, Lawton CA, Krisch RE, Wolkov HB, Movsas B, et al. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma-long-term results of phase III RTOG 85-31. . Int J Radiat Oncol Biol Phys 2005;61:1285–90.
   PubMed Web of Science ®Google Scholar
• Granfors T, Modig H, Damber JE, Tomic R. Long-term followup of a randomized study of locally advanced prostate cancer treated with combined orchiectomy and external radiotherapy versus radiotherapy alone. J Urol 2006;176:544–7.
   PubMed Web of Science ®Google Scholar
• Dorff TB, Flaig TW, Tangen CM, Hussain MHA, Swanson GP, Wood DP, et al. Adjuvant androgen deprivation for high-risk prostate cancer after radical prostatectomy: SWOG S9921 study. J Clin Oncol 2011;29:2040–5.
   PubMed Web of Science ®Google Scholar
• Shipley W, Hunt D, Lukka H, Major P, Heney M, Grignon D, et al. Initial report of RTOG 9601: A phase III trial in prostate cancer: Anti-androgen therapy (AAT) with bicalutamide during and after radiation therapy (RT) improves freedom from progression and reduces the incidence of metastatic disease in patients following radical prostatectomy (RP) with pT2-3, N0 disease, and elevated PSA levels. Int J Radiat Oncol Biol Phys 2010;78:58
   PubMed Web of Science ®Google Scholar
• Horwitz EM, Bae K, Hanks GE, Porter A, Grignon DJ, Brereton HD, et al. Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer. J Clin Oncol 2008;26:2497–504.
   PubMed Web of Science ®Google Scholar
• D’amico AV, Chen M-H, Renshaw AA, Loffredo M, Kantoff PW. Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial. JAMA 2008;299:289–95.
   PubMed Web of Science ®Google Scholar
• Bolla M, Maingon P, van den Bergh A, Carrie C, Villa S, Kitsios P, et al. Results of EORTC 22991: 3D-CRT/IMRT with or without 6-month androgen deprivation therapy in localized T1b-cT2aN0M0 prostate cancer (EORTC 22991). Eur Urol Suppl 2014;13:104–5.
   Google Scholar
• Bolla M, Van Tienhoven G, Warde P, Dubois JB, Mirimanoff RO, Storme G, et al. External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study. Lancet Oncol 2010;11:1066–73.
   PubMed Web of Science ®Google Scholar
• Bolla M, Gonzalez D, Warde P, Dubois JB, Mirimanoff R-O, Storme G, et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 1997;337:295–300.
   PubMed Web of Science ®Google Scholar
• Bolla M, de Reijke TM, Van Tienhoven G, Van den Bergh ACM, Oddens J, Poortmans PMP, et al. Duration of androgen suppression in the treatment of prostate cancer. N Engl J Med 2009;360:2516–27.
   PubMed Web of Science ®Google Scholar
• Messing EM, Manola J, Yao J, Kiernan M, Crawford D, Wilding G, et al. Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol 2006;7:472–9.
   PubMed Web of Science ®Google Scholar
• Studer UE, Whelan P, Wimpissinger F, Casselman J, de Reijke TM, Knönagel H, et al. Differences in time to disease progression do not predict for cancer-specific survival in patients receiving immediate or deferred androgen-deprivation therapy for prostate cancer: final results of EORTC randomized trial 30891 with 12 years of follow-up. Eur Urol 2014;66:829–38.
   PubMed Web of Science ®Google Scholar
• Schröder FH, Kurth K-H, Fossa SD, Hoekstra W, Karthaus PP, De Prijck L, et al. Early versus delayed endocrine treatment of T2-T3 pN1-3 M0 prostate cancer without local treatment of the primary tumour: Final results of European Organisation for the Research and Treatment of Cancer protocol 30846 after 13 years of follow-up a randomi. Eur Urol 2009;55:14–22.
   PubMed Web of Science ®Google Scholar
• Walsh P. On behalf of TMRCPCWP investigators group. Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council trial. Br J Urol 1997;158:1623–4.
   Google Scholar
• Tran C, Ouk S, Clegg NJ, Chen Y, Watson PA, Arora V, et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 2009;324:787–90.
   PubMed Web of Science ®Google Scholar
• Scher HI, Fizazi K, Saad F, Taplin M-E, Sternberg CN, Miller K, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012;367:1187–97.
   PubMed Web of Science ®Google Scholar
• Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, Higano CS, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med 2014;371:424–33.
   PubMed Web of Science ®Google Scholar
• Attard G, Reid AHM, Yap TA, Raynaud F, Dowsett M, Settatree S, et al. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol 2008;26:4563–71.
   PubMed Web of Science ®Google Scholar
• Fizazi K, Scher HI, Molina A, Logothetis CJ, Chi KN, Jones RJ, et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study707. Lancet Oncol 2012;13:983–92.
   PubMed Web of Science ®Google Scholar
• Ryan CJ, Smith MR, De Bono JS, Molina a, Logothetis CJ, De Souza P, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy314. N Engl J Med 2013;368:138–48.
   PubMed Web of Science ®Google Scholar
• Ryan CJ, Smith MR, Fizazi K, Saad F, Mulders PFA, Sternberg CN, et al. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 2015;16:152–60.
   PubMed Web of Science ®Google Scholar
• Thomsen FB, Brasso K, Christensen IJ, Johansson J-E, Angelsen A, Tammela TLJ, et al. Survival benefit of early androgen receptor inhibitor therapy in locally advanced prostate cancer: long-term follow-up of the SPCG-6 study. Eur J Cancer 2015;51:1283–92.
   PubMed Web of Science ®Google Scholar
• Antonarakis ES, Feng Z, Trock BJ, Humphreys EB, Carducci MA, Partin AW, et al. The natural history of metastatic progression in men with prostate-specific antigen recurrence after radical prostatectomy: long-term follow-up. BJU Int 2012;109:32–9.
   PubMed Web of Science ®Google Scholar
• Taplin M-E, Montgomery B, Logothetis CJ, Bubley GJ, Richie JP, Dalkin BL, et al. Intense androgen-deprivation therapy with abiraterone acetate plus leuprolide acetate in patients with localized high-risk prostate cancer: results of a randomized phase II neoadjuvant study. J Clin Oncol 2014;32:3705–15.
   PubMed Web of Science ®Google Scholar
• Eulau SM, Tate DJ, Stamey TA, Bagshaw MA, Hancock SL. Effect of combined transient androgen deprivation and irradiation following radical prostatectomy for prostatic cancer. Int J Radiat Oncol Biol Phys 1998;41:735–40.
   PubMed Web of Science ®Google Scholar
• King CR, Presti JC, Gill H, Brooks J, Hancock SL. Radiotherapy after radical prostatectomy: does transient androgen suppression improve outcomes? Int J Radiat Oncol Biol Phys 2004;59:341–7.
   PubMed Web of Science ®Google Scholar
• Parker C, Sydes MR, Catton C, Kynaston H, Logue J, Murphy C, et al. Radiotherapy and androgen deprivation in combination after local surgery (RADICALS): a new Medical Research Council/National Cancer Institute of Canada phase III trial of adjuvant treatment after radical prostatectomy. BJU Int 2007;99:1376–9.
   PubMed Web of Science ®Google Scholar
• Gakis G, Boorjian SA, Briganti A, Joniau S, Karazanashvili G, Karnes RJ, et al. The role of radical prostatectomy and lymph node dissection in lymph node-positive prostate cancer: a systematic review of the literature. Eur Urol 2014;66:191–9.
   PubMed Web of Science ®Google Scholar
• Crook JM, O’Callaghan CJ, Duncan G, Dearnaley DP, Higano CS, Horwitz EM, et al. Intermittent androgen suppression for rising PSA level after radiotherapy. N Engl J Med 2012;367:895–903.
   PubMed Web of Science ®Google Scholar
• Sweeney CJ, Chen Y-H, Carducci M, Liu G, Jarrard DF, Eisenberger M, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med 2015;373:737–46.
   PubMed Web of Science ®Google Scholar
• James ND, Sydes MR, Mason MD, Clarke NW, Dearnaley DP, Spears MR, et al. Docetaxel and/or zoledronic acid for hormone-naïve prostate cancer. First overall survival results from STAMPEDE (NCT00268476). J Clin Oncol 2015;9:S162–64.
   Google Scholar
• Gravis G, Fizazi K, Joly F, Oudard S, Priou F, Esterni B, et al. Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial. Lancet Oncol 2013;14:149–58.
   PubMed Web of Science ®Google Scholar